Stockreport

MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MYOKARDIA  (MYOK) 
Last myokardia earnings: 2/27 04:05 pm Check Earnings Report
PDF Phase 2 Study Met Primary and Key Secondary Endpoints Results from First Patient Cohort of PIONEER-HCM Accepted for Oral Presentation at Heart Failure Society of Ameri [Read more]